SCI/D
8
1
3
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
12.5%
1 terminated out of 8 trials
66.7%
-19.8% vs benchmark
13%
1 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (8)
Effect of Hypercapnia Treatment on Respiratory Recovery After Spinal Cord Injury
Conditioning SCID Infants Diagnosed Early
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
Methadone as an Alternative Treatment for Children Underdoing HSCT
JSP191 Antibody Targeting Conditioning in SCID Patients
Novel by Upper Airway Respiratory Muscle Training to Treat OSA in Chronic SCI
Participation in a Research Registry for Immune Disorders
Patients Treated for SCID (1968-Present)